Risk management for analytical methods based on the total error concept: Conciliating the objectives of the pre-study and in-study validation phases
暂无分享,去创建一个
Walthère Dewé | Bruno Boulanger | Myriam Maumy-Bertrand | Bernadette Govaerts | Aurelie Gilbert | B. Govaerts | B. Boulanger | M. Maumy-Bertrand | W. Dewé | A. Gilbert
[1] Philippe Hubert,et al. The SFSTP guide on the validation of chromatographic methods for drug bioanalysis: from the Washington Conference to the laboratory , 1999 .
[2] Robert W. Mee. β-Expectation and β-Content Tolerance Limits for Balanced One-Way ANOVA Random Model , 1984 .
[3] Philippe Hubert,et al. Objectives of pre-study validation and decision rules , 2000 .
[4] Fred Spiring,et al. Introduction to Statistical Quality Control , 2007, Technometrics.
[5] M Laurentie,et al. Harmonization of strategies for the validation of quantitative analytical procedures. A SFSTP proposal--part II. , 2004, Journal of pharmaceutical and biomedical analysis.
[6] Krys J. Miller,et al. Workshop on Bioanalytical Methods Validation for Macromolecules: Summary Report , 2001, Pharmaceutical Research.
[7] Patrice Chiap,et al. Méthodes chromatographiques de dosage dans les milieux biologiques : Stratégie de validation , 1996 .
[8] J. W. Findlay,et al. Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. , 2000, Journal of pharmaceutical and biomedical analysis.
[9] W C Smith,et al. Conceptual and statistical issues in the validation of analytic dilution assays for pharmaceutical applications. , 1998, Journal of biopharmaceutical statistics.
[10] D L Massart,et al. Validation of bioanalytical chromatographic methods. , 1998, Journal of pharmaceutical and biomedical analysis.
[11] P. Chiap,et al. An analysis of the SFSTP guide on validation of chromatographic bioanalytical methods: progress and limitations. , 2003, Journal of pharmaceutical and biomedical analysis.
[12] David Hoffman,et al. TWO-SIDED TOLERANCE INTERVALS FOR BALANCED AND UNBALANCED RANDOM EFFECTS MODELS , 2005, Journal of biopharmaceutical statistics.
[13] Vinod P. Shah,et al. Bioanalytical Method Validation—A Revisit with a Decade of Progress , 2000, Pharmaceutical Research.
[14] G. B. Wetherill,et al. Quality Control and Industrial Statistics , 1975 .
[15] Binodh DeSilva,et al. Recommendations for the Bioanalytical Method Validation of Ligand-Binding Assays to Support Pharmacokinetic Assessments of Macromolecules , 2003, Pharmaceutical Research.
[16] Philippe Hubert,et al. Analyse statistique des résultats de validation de méthodes d’analyse chromatographiques , 2000 .
[17] Robert W. Mee. Estimation of the percentage of a normal distribution lying outside a specified interval , 1988 .
[18] Robert W. Mee. β-Expectation and β-Content Tolerance Limits for Balanced One-Way ANOVA Random Model@@@b-Expectation and b-Content Tolerance Limits for Balanced One-Way ANOVA Random Model , 1984 .
[19] Robert O. Kringle,et al. An Assessment of the 4-6-20 Rule for Acceptance of Analytical Runs in Bioavailability, Bioequivalence, and Pharmacokinetic Studies , 1994, Pharmaceutical Research.
[20] Caporal-Gautier,et al. Guide de validation analytique. Rapport d'une commission SFSTP. I : Méthodologie , 1992 .
[21] Philippe Hubert,et al. Conciliating objectives of analytical methods and objectives of validation : a statistical perspective , 2006 .